Opinion
Video
Author(s):
Panelists discuss how clinical management of CAR T-cell therapy–associated toxicities focuses primarily on early recognition and prompt intervention with tocilizumab and/or corticosteroids for cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome (ICANS), following established grading systems and treatment algorithms.
Video content above is prompted by the following
What is your approach to managing toxicities such as CRS and ICANS?